Ovid Therapeutics Inc. (OVID): Price and Financial Metrics


Ovid Therapeutics Inc. (OVID)

Today's Latest Price: $6.29 USD

0.30 (5.01%)

Updated Nov 27 1:00pm

Add OVID to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

OVID Stock Price Chart Interactive Chart >

Price chart for OVID

OVID Price/Volume Stats

Current price $6.29 52-week high $9.40
Prev. close $5.99 52-week low $1.80
Day low $6.08 Volume 502,200
Day high $6.30 Avg. volume 944,260
50-day MA $5.68 Dividend yield N/A
200-day MA $5.24 Market Cap 399.01M

Ovid Therapeutics Inc. (OVID) Company Bio


Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.


OVID Latest News Stream


Event/Time News Detail
Loading, please wait...

OVID Latest Social Stream


Loading social stream, please wait...

View Full OVID Social Stream

Latest OVID News From Around the Web

Below are the latest news stories about Ovid Therapeutics Inc that investors may wish to consider to help them evaluate OVID as an investment opportunity.

Ovid's soticlestat shows positive effect in rare epilepsies

Ovid Therapeutics (OVID) reported results from Phase 2 ARCADE and ENDYMION studies evaluating soticlestat (OV935/TAK-935) in patients with CDKL5 deficiency disorder ((CDD)) and Dup15q syndrome (Dup15q), two rare developmental and epileptic encephalopathies. Data from both the studies showed seizure frequency reduction over time, and soticlestat was well tolerated.In 12 CDD patients, median reductions of...

Seeking Alpha | September 30, 2020

Ovid Therapeutics (OVID) Investor Presentation - Slideshow

The following slide deck was published by Ovid Therapeutics Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 17, 2020

3 Top Biotech Stocks to Buy Now

While large-cap biotech companies have been doing quite well, investors can frequently find market-beating performance in emerging biotechs developing cutting-edge treatments. First up is Ovid Therapeutics (NASDAQ: OVID), with a $365 million market cap This company is developing a treatment for Angelman syndrome, a genetic disease causing profound developmental delay in children. The treatment, called OV101, is designed to mitigate excessive neurotransmission between neurons that is thought to contribute to Angelman syndrome.

Yahoo | July 25, 2020

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome

* Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome * Ovid and UConn to collaborate on genetic therapy for potential future use alone or in combination with OV101, Ovid’s small molecule therapy for Angelman syndrome in Phase 3 developmentNEW YORK and FARMINGTON, Conn., July 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, and the University of Connecticut School of Medicine (“UConn”), today announced a research collaboration and license agreeme...

Yahoo | July 23, 2020

Is Ovid Therapeutics Stock a Buy?

Shares of Ovid Therapeutics (NASDAQ: OVID) have more than doubled over the past four months, a performance the clinical-stage biotech company owes in part to a positive rating from an analyst. In March and again in June, Ladenburg Thalmann analyst Michael Higgins gave the stock a $20 price target. The biotech has a handful of potential treatments in its pipeline, the most advanced of which is OV101, which targets Angelman syndrome.

Yahoo | July 14, 2020

Read More 'OVID' Stories Here

OVID Price Returns

1-mo 23.09%
3-mo 9.58%
6-mo 13.74%
1-year 47.65%
3-year -48.90%
5-year N/A
YTD 51.57%
2019 71.49%
2018 -75.48%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9587 seconds.